MX2021002657A - Nuevos conjugados de montelukast y péptidos. - Google Patents

Nuevos conjugados de montelukast y péptidos.

Info

Publication number
MX2021002657A
MX2021002657A MX2021002657A MX2021002657A MX2021002657A MX 2021002657 A MX2021002657 A MX 2021002657A MX 2021002657 A MX2021002657 A MX 2021002657A MX 2021002657 A MX2021002657 A MX 2021002657A MX 2021002657 A MX2021002657 A MX 2021002657A
Authority
MX
Mexico
Prior art keywords
sub
peptide
containing compound
montelukast
sup
Prior art date
Application number
MX2021002657A
Other languages
English (en)
Spanish (es)
Inventor
Ming Gu
Bengt Ingemar Samuelsson
Original Assignee
Jiangyin Usun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangyin Usun Pharmaceutical Co Ltd filed Critical Jiangyin Usun Pharmaceutical Co Ltd
Publication of MX2021002657A publication Critical patent/MX2021002657A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021002657A 2018-09-14 2019-09-14 Nuevos conjugados de montelukast y péptidos. MX2021002657A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018105703 2018-09-14
CN2018119072 2018-12-04
PCT/CN2019/105832 WO2020052677A1 (en) 2018-09-14 2019-09-14 New conjugates of montelukast and peptides

Publications (1)

Publication Number Publication Date
MX2021002657A true MX2021002657A (es) 2021-07-21

Family

ID=69777394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002657A MX2021002657A (es) 2018-09-14 2019-09-14 Nuevos conjugados de montelukast y péptidos.

Country Status (27)

Country Link
US (2) US11680082B2 (cg-RX-API-DMAC7.html)
EP (2) EP3678705B1 (cg-RX-API-DMAC7.html)
JP (1) JP7759693B2 (cg-RX-API-DMAC7.html)
KR (1) KR102946621B1 (cg-RX-API-DMAC7.html)
CN (2) CN111601618A (cg-RX-API-DMAC7.html)
AU (1) AU2019338582B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004823A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112420A1 (cg-RX-API-DMAC7.html)
DK (1) DK3678705T5 (cg-RX-API-DMAC7.html)
ES (1) ES2956509T3 (cg-RX-API-DMAC7.html)
FI (1) FI3678705T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230946T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062848T2 (cg-RX-API-DMAC7.html)
IL (1) IL281426A (cg-RX-API-DMAC7.html)
LT (1) LT3678705T (cg-RX-API-DMAC7.html)
MX (1) MX2021002657A (cg-RX-API-DMAC7.html)
MY (1) MY205435A (cg-RX-API-DMAC7.html)
PL (1) PL3678705T3 (cg-RX-API-DMAC7.html)
PT (1) PT3678705T (cg-RX-API-DMAC7.html)
RS (1) RS64436B1 (cg-RX-API-DMAC7.html)
SA (1) SA521421448B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102119RA (cg-RX-API-DMAC7.html)
SI (1) SI3678705T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300210T1 (cg-RX-API-DMAC7.html)
TW (1) TWI875712B (cg-RX-API-DMAC7.html)
WO (1) WO2020052677A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101398B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3068818A1 (en) * 2017-07-05 2019-01-10 Jiangyin Mucocare Pharmaceutical Co., Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
EP4028409A4 (en) * 2019-09-14 2023-10-11 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. NEW PEPTIDES
US20240218016A1 (en) * 2019-12-02 2024-07-04 Shenzhen Institutes Of Advanced Technology Peptides and their use in the treatment of inflammation
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2021207606A1 (en) * 2020-04-10 2021-10-14 University Of Georgia Research Foundation, Inc. Methods for treatment of coronavirus infections
KR102596264B1 (ko) * 2020-11-30 2023-11-01 주식회사 바이오빛 기능성 펩티드가 결합된 생체적합 폴리펩티드를 포함하는 염증 질환의 억제용 조성물
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
WO2022193185A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New conjugates
WO2023225107A1 (en) * 2022-05-17 2023-11-23 Emory University Diroximel fumarate, inhalation administration methods, pharmaceutical uses and compositions
JP2026506026A (ja) * 2023-02-13 2026-02-20 エンリティザ(シャンハイ)ファーマシューティカル カンパニー リミテッド 新規多機能オリゴペプチド
AU2024312518A1 (en) * 2023-06-22 2026-01-22 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
CN122028898A (zh) * 2023-10-23 2026-05-12 艾缇亚(上海)制药有限公司 新型短链肽及其衍生物
WO2025110754A1 (ko) * 2023-11-22 2025-05-30 한도숙 상처 치료 또는 피부 주름형성 억제용 조성물
WO2025195444A1 (en) 2024-03-20 2025-09-25 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New use of peptides derived from vasoactive intestinal peptide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
WO2003020200A2 (en) 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2004005309A2 (en) 2002-07-08 2004-01-15 Pliva - Istrazivacki Institut D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
US20050107612A1 (en) 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
KR101224235B1 (ko) * 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 il­9 항체 및 그의 용도
US7582297B2 (en) * 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
JP2007510621A (ja) 2003-07-29 2007-04-26 シグニチャー アールアンドディー ホールディングス,エルエルシー. アミノ酸プロドラッグ
DE602005018672D1 (de) * 2004-10-27 2010-02-11 Glaxosmithkline Zagreb Konjugate mit entzündungshemmender aktivität
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
CA2773737C (en) * 2009-09-09 2021-11-16 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
CN102068432A (zh) 2011-01-11 2011-05-25 李仲昆 一种由他定类和白三烯拮抗剂组成的外用复方组合物
WO2012112690A2 (en) * 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
HK1207562A1 (en) 2012-01-18 2016-02-05 苏州泰飞尔医药有限公司 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
EP2968309A4 (en) * 2013-03-13 2016-08-31 Inflammatory Response Res Inc USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY
US20160060328A1 (en) * 2013-10-25 2016-03-03 Lpath, Inc. Compositions and methods for binding cysteinyl leukotrienes (cyslts) for treatment of disease
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
BR112018000953A2 (pt) 2015-07-20 2018-09-11 Bengt I. Samuelsson Institute Of Life Science Research produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele
CN110945016A (zh) 2017-05-24 2020-03-31 特拉斯福特普拉斯公司 用于治疗炎性疾病的肽化合物、缀合化合物及其用途
CA3068818A1 (en) * 2017-07-05 2019-01-10 Jiangyin Mucocare Pharmaceutical Co., Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
CN110139662B (zh) * 2017-07-05 2022-03-18 江阴贝瑞森制药有限公司 肽的抗炎用途

Also Published As

Publication number Publication date
WO2020052677A1 (en) 2020-03-19
ES2956509T3 (es) 2023-12-22
EP3678705A4 (en) 2021-06-09
AU2019338582B2 (en) 2026-01-15
JP7759693B2 (ja) 2025-10-24
TW202023623A (zh) 2020-07-01
PL3678705T3 (pl) 2023-10-09
PT3678705T (pt) 2023-07-19
ZA202101398B (en) 2022-09-28
SG11202102119RA (en) 2021-04-29
US11680082B2 (en) 2023-06-20
HUE062848T2 (hu) 2023-12-28
KR20210061372A (ko) 2021-05-27
EP3678705A1 (en) 2020-07-15
US20230348536A1 (en) 2023-11-02
RS64436B1 (sr) 2023-09-29
CN116785447B (zh) 2024-11-22
DK3678705T3 (en) 2023-06-26
IL281426A (en) 2021-04-29
SMT202300210T1 (it) 2023-09-06
MY205435A (en) 2024-10-21
SI3678705T1 (sl) 2023-10-30
JP2022500437A (ja) 2022-01-04
CN116785447A (zh) 2023-09-22
SA521421448B1 (ar) 2024-03-14
EP4253404A2 (en) 2023-10-04
CA3112420A1 (en) 2020-03-19
AU2019338582A1 (en) 2020-11-19
EP3678705B1 (en) 2023-05-31
EP4253404A3 (en) 2023-12-13
DK3678705T5 (da) 2024-09-16
FI3678705T3 (fi) 2023-07-04
HRP20230946T1 (hr) 2023-11-24
US20210309696A1 (en) 2021-10-07
CN111601618A (zh) 2020-08-28
LT3678705T (lt) 2023-08-10
KR102946621B1 (ko) 2026-04-01
TWI875712B (zh) 2025-03-11
BR112021004823A2 (pt) 2021-06-08

Similar Documents

Publication Publication Date Title
EP4253404A3 (en) Conjugates of montelukast and peptides
AU653524B2 (en) New imidazole derivatives, their preparation process, the new intermediates obtained, their use as medicaments and the pharmaceutical compositions containing them
CO2025013480A2 (es) Compuestos de pirido[4,3–d]pirimidina
MX2022003057A (es) Nuevos peptidos.
EA201170193A1 (ru) Новые содержащие серу липиды для применения в качестве пищевой добавки или в качестве лекарственного средства
ECSP23002606A (es) Nuevo inhibidor de la secreción de ácido y uso del mismo
ECSP067058A (es) Nuevos derivados de piridazin-3(2h)-ona
WO2009067639A3 (en) Variants of c-type natriuretic peptide
IL275188B2 (en) Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis
PE20211390A1 (es) Compuestos antibacterianos
AR062051A1 (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d₂
JP2018520999A5 (cg-RX-API-DMAC7.html)
WO2024189598A3 (en) Acylsulfonamide kat6a inhibitors
MX2020007994A (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
WO2012059442A3 (en) Neurotrypsin inhibitors
MX2024006556A (es) Inhibidores de peptido del receptor de interleucina-23.
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MX2025014276A (es) Heterociclos biciclicos 5,6 insaturados utiles como inhibidores de la proteina receptora 3 similar a nod
CN105800802A (zh) 一种复合型无磷缓蚀阻垢剂
BR112020006576A8 (pt) Sal ácido conjugado de n, n-dimetilglicina com ácido orgânico, composição e utilização.
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
ZA202308193B (en) Functionalized long-chain carboxylic acids, and their use for treatment of disease
ES2993255T3 (en) Dihydro-cyclopenta-isoquinoline derivatives
CN105348365A (zh) 一种胆酸衍生物及其制备方法、药物组合物和用途
CN102134269A (zh) 糖皮质激素硝酰氧基衍生物